Product Description
Rimonabant puehu video
Raw Rimonabant pauda mau huapalapala
| Name: | ʻO ka pauka Rimonabant (SR141716) |
| CAS: | 168273-06-1 |
| Nā Kaulike Molecular: | C22H21Cl3N4O |
| Molecular Weight: | 463.8 |
| Wahi Manaʻo: | 230 ° C - 240 ° C |
| Hōʻoia Kōkua: | Pauka -20°C 3 makahiki |
| kala like 'ole: | pauda hina-keʻokeʻo |
Rimonabant Background
Hoʻomaka ka mōʻaukala o Rimonabant i ka hopena o 1990s a me ka 2000 mua i ka wā i hoʻomaka ai nā mea noiʻi e noiʻi i ka ʻōnaehana endocannabinoid a me kāna mau hopena i nā kaʻina physiological like ʻole, me ka hoʻoponopono ʻana i ka makemake a me ke koena o ka ikehu.
I loko o kēia manawa, ua ʻike nā kānaka ʻepekema i nā mea loaʻa cannabinoid i loko o ke kino, i kapa ʻia ʻo CB1 receptors, ka mea i ʻike nui ʻia i loko o ka lolo a me nā ʻiʻo peripheral.
Hoʻoikaika ʻia e ka ulu ʻana o ka ʻike e pili ana i ka ʻōnaehana endocannabinoid i ka mālama ʻana i ka makemake, ua hoʻomaka nā hui lāʻau lapaʻau i ka hoʻomohala ʻana i nā antagonists koho CB1 e hoʻopaʻa i ka momona a me nā kūlana pili.
I ka makahiki 1999, ua hoʻomaka ka hui lāʻau lapaʻau Farani ʻo Sanofi-Synthélabo (ʻo Sanofi i kēia manawa) e hoʻomohala i kahi lāʻau i kapa ʻia ʻo Rimonabant.
Ua mālama ʻia nā hoʻokolohua lapaʻau e loiloi i ka pono a me ka palekana o Rimonabant i ka mālama ʻana i ka momona a me nā maʻi metabolic pili.
Ma muli o nā hopena maikaʻi mai kēia mau hoʻāʻo ʻana, ua loaʻa iā Rimonabant ka ʻae kānāwai i ka makahiki 2006 ma ka European Union ma lalo o ka inoa kalepa ʻo Acomplia.
Eia naʻe, ʻoiai ʻo kona kūleʻa mua, ua kū ʻo Rimonabant i nā pilikia a me nā hoʻopaʻapaʻa. ʻO nā hōʻike o nā hopena ʻaoʻao psychiatric, me ke kaumaha, ka hopohopo, a me ka manaʻo suicidal, ua puka mai i ka wā o ka nānā ʻana ma hope o ka mākeke. kekahi mau ʻāina, me ka European Union ma 2008.
ʻO ka haʻalele ʻana o Rimonabant i hōʻike i ke koʻikoʻi o ka loiloi pono ʻana i ka palekana a me nā pilikia psychiatric e pili ana i nā lāʻau lapaʻau e kuhikuhi ana i ka ʻōnaehana endocannabinoid. ʻōnaehana a me ka hoʻoponopono metabolic.
Mai ka haʻalele ʻana o Rimonabant, ua hoʻomau nā noiʻi noiʻi e ʻimi i ka hiki ke hoʻopaʻa i ka ʻōnaehana endocannabinoid, akā me ka manaʻo nui i ka hoʻomohala ʻana i nā pūhui e hoʻēmi i nā pilikia psychiatric e pili ana me CB1 receptor blockade.
Pauda Rimonabant
ʻO Rimonabant Powder kahi lāʻau lapaʻau i loaʻa i ka nānā no kona hoʻohana pono ʻana i ka lāʻau lapaʻau. No ka papa o nā lāʻau i kapa ʻia ʻo selective cannabinoid receptor antagonists. ʻai a me ke kaumaha.
ʻO ke ʻano o ka pauka o Rimonabant hiki ke maʻalahi i ka lawelawe ʻana a me ka hoʻopuehu ʻana i nā kaʻina hana. propylene glycol. ʻO nā hiʻohiʻona solubility o Rimonabant he mea nui e noʻonoʻo ai i ka wā o ka hoʻomohala ʻana.
ʻO ke ʻano hana o Rimonabant
ʻO ka hana o ka hana a Rimonabant e pili ana i kāna pilina me ka ʻōnaehana endocannabinoid i loko o ke kino.
Ke hoʻohana ʻia, hoʻopaʻa ʻia ʻo Rimonabant a hoʻopaʻa i nā mea hoʻokipa CB1, e pale ana i ka hoʻāla ʻana o kēia mau mea loaʻa e nā cannabinoids endogenous e like me anandamide. ka hoʻoponopono, ke kaulike o ka ikehu, a me ka lipid metabolism.
ʻO ke kikoʻī, ʻo ka blockade o CB1 receptors e Rimonabant e pili ana i kēia:
Mana Manaʻo Appetite
Hoʻokomo ʻia nā mea loaʻa CB1 i ka hoʻoponopono ʻana i ka makemake a me ka ʻai ʻana i ka meaʻai. Ke hoʻāla ʻia nā mea hoʻokipa CB1, hoʻoulu lākou i ka hoʻokuʻu ʻana i nā neuropeptides hoʻoulu i ka pōloli a hoʻonui i nā waiwai waiwai o ka meaʻai. i ka emi ʻana o ka ʻai a me ka hoʻemi ʻana i ka ʻai.
Hoolilo Imi
Hoʻopili ka ʻōnaehana endocannabinoid i ka hoʻolilo ʻana i ka ikehu ma o ka hoʻoponopono ʻana i ka thermogenesis, ke kaʻina hana e hana ai ke kino i ka wela a puhi i nā calorie.
Lipid Metabolism
Hoʻopili ʻia ka hoʻāla ʻana o CB1 me ka hoʻonui ʻana i ka lipogenesis (ka mālama ʻana i ka momona) a me ka emi ʻana o ka lipolysis (faʻihaʻi momona).
He mea nui e hoʻomaopopo ʻoiai ʻo Rimonabant e hana nui ma ke ʻano he CB1 receptor antagonist, hiki ke hōʻike i kekahi mau hopena hou a i ʻole ka launa pū ʻana me nā mea loaʻa a i ʻole nā pūnaewele i loko o ke kino. noiʻi.
ʻO keʻano o ka hana o ka Rimonabant Powder e like me ka Rimonabant ma kona mauʻano'ē aʻe. Rimonabant Powder e pili ana i ka Powdered form of the drug Rimonabant,ʻo ia ka mea koho cannabinoid receptor antagonist.
Ke lawelawe ʻia ʻo Rimonabant Powder, ma ka waha a i ʻole ma o ka hoʻopili ʻana i nā ʻano ʻano like ʻole, e hoʻopau ʻia a komo i loko o ke kino.
He aha nā hopena o Rimonabant?
Ua hoʻokumu mua ʻia ʻo Rimonabant, kahi lāʻau anti-obesity e kōkua i ka poʻe e hakakā nei me ka mālama ʻana i ke kaumaha.
Pākuʻi Kaomi
Ua hoʻolālā ʻia ʻo Rimonabant e hōʻemi i ka ʻai a hoʻoikaika i ka pohō kaumaha ma ke kāohi ʻana i nā mea loaʻa CB1 i loko o ka lolo e pili ana i ka hoʻoponopono ʻana i ka ʻai.
Weight Loss
Ma muli o ka hoʻopau ʻana i ka ʻai, ua manaʻo ʻia ʻo Rimonabant e alakaʻi i ke kaumaha o ka poʻe me ka momona a i ʻole ke kaumaha.
Hoʻomaikaʻi Metabolic
Ua hōʻike ʻo Rimonabant i nā pono kūpono i ka hoʻomaikaʻi ʻana i nā ʻāpana metabolic e pili ana i ka momona, e like me ka lipid profiles, insulin resistance, a me nā hōʻailona o ka pilikia cardiovascular.
Kokua Hooki Puhi
Ua noiʻi ʻia ʻo Rimonabant no kona hoʻohana ʻana ma ke ʻano he kōkua i ka hoʻopau ʻana i ka uahi.
No ke aha ke kumu o Rimonabant i ke kaumaha?
ʻAʻole i hoʻomaopopo piha ʻia nā hana pololei e hiki ai iā Rimonabant ke alakaʻi i ke kaumaha. Akā naʻe, ua manaʻo nā noiʻi a me nā hōʻike lapaʻau i kahi pilina ma waena o ka hoʻohana ʻana iā Rimonabant a me ka piʻi ʻana o ke kaumaha a me nā hopena psychiatric ʻē aʻe.
ʻO Rimonabant, ma ke ʻano he cannabinoid receptor antagonist koho, poloka i ka hana o nā mea loaʻa CB1 i loko o ka ʻōnaehana endocannabinoid. Hoʻokani nā mea hoʻokipa CB1 i nā kaʻina hana physiological like ʻole, me ka hoʻoponopono ʻana o ka naʻau a me ka hoʻoponopono ʻana. ʻōnaehana endocannabinoid, hiki ke kōkua i nā loli i ke ʻano a me ka maikaʻi o ka noʻonoʻo.
Hoʻohui ʻia, pili ka ʻōnaehana endocannabinoid i ka hoʻoponopono ʻana i nā pane koʻikoʻi a me ka modulation o nā neurotransmitters e like me serotonin, ka mea i ʻike ʻia he kuleana koʻikoʻi i ka hoʻoponopono ʻana i ke ʻano.
He mea nui e hoʻomaopopo he ʻokoʻa ka pane ʻana o kēlā me kēia kanaka i nā lāʻau lapaʻau, ʻaʻole nā mea a pau e lawe iā Rimonabant e ʻike i ke kaumaha a i ʻole nā hopena pili pili. mākeke ma nā ʻāina he nui. No laila, i kēia manawa ʻaʻole maʻalahi ke kūʻai ʻana i ka Rimonabant Powder ma ka hale kūʻai kūloko.
Inā hopohopo ʻoe e pili ana i ke kaumaha a i ʻole nā pilikia e pili ana i ke olakino noʻonoʻo, he mea koʻikoʻi ia e kamaʻilio me ke kauka olakino no ka loiloi kūpono a me ke alakaʻi.
ʻO ka wehe ʻana o Rimonabant a me ka noiʻi mau
Ma muli o nā pilikia palekana, ʻoi aku ka nui o nā hopena psychiatric, ua hoʻihoʻi ʻia ʻo Rimonabant mai ka mākeke ma kekahi mau ʻāina. .
Hiki i ka noiʻi e hiki mai ana ke hoʻomaʻemaʻe i ka ʻike o ka ʻōnaehana endocannabinoid, ka ʻimi ʻana i nā noi kūpono o ka modulation endocannabinoid i nā ʻano olakino like ʻole, a me ka hoʻomohala ʻana i nā lāʻau lapaʻau palekana a ʻoi aku ka maikaʻi ma kēia kahua.
Ma hea e kūʻai ai i ka pauka Rimonabant?
He mea nui e hoʻomaopopo i ka nui o ka Rimonabant Powder no ke kūʻai aku ma ka pūnaewele. ʻAʻole hiki ke loaʻa no ke kūʻai a hoʻohana paha. nā waiwai, e hana ana i nā hoʻokolohua preclinical a me nā hoʻokolohua, a me ka hoʻokumu ʻana i nā huahana lāʻau hou. kā lākou HPLC kūʻokoʻa a me COA hōʻike. ʻO AASRAW kahi mea hoʻolako hilinaʻi e hilinaʻi. Hāʻawi mākou i ka maikaʻi Rimonabant Powder. No ke kauoha kūʻai nui o Rimonabant Powder, e loaʻa iā ʻoe ke kumukūʻai hoʻokūkū.
Rimonabant Powder Testing Report-HNMR
He aha ka HNMR a He aha ka HNMR spectrum e haʻi aku iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā hui pū ʻia i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR e hoʻohālikelike i nā hale waihona puke spectral a i ʻole e kuhi pololei i ke ʻano kumu. Ke ʻike ʻia ke ʻano kumu, hiki ke hoʻohana ʻia ka NMR no ka hoʻoholo ʻana i ka conformation molecular i ka hopena a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, nā hoʻololi ʻana, ka solubility, a me ka diffusion.
Pehea e kūʻai ai i ka pauka Rimonabant mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu whatsapp iā mākou, e hoʻopili kā mākou mea kūʻai aku (CSR) me ʻoe i loko o 12 mau hola.
❷E hāʻawi mai iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala hoʻouna a me ka lā i manaʻo ʻia (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Shira Hirsch
ʻO ka Obesity a me ka Metabolism Laboratory, POB 12065, Ierusalema 9112001, ʻIseraʻela
2. Dalal AlKhelb
Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA
3. Robert Ettaro
'Oihana o Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA
4. Alessandra Porcu
'Oihana o Biomedical Sciences, University of Cagliari, 09042, Monserrato, Italia
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
E hoʻomaopopo '
[1] Soyka M. "Rimonabant and depression."Pharmacopsychiatry.2008 Sep;41(5):204-5.doi: 10.1055/s-2008-1078744.Epub 2008 Sep 1.PMID: 18763226
[2] Boyd ST, Fremming BA. Ann Pharmacother.1 Apr;2005(39):4-684.doi: 90/aph.10.1345E1.Epub 499 Mar 2005.PMID: 8
[3] Curioni C,André C.”Rimonabant no ke kaumaha nui a me ka momona.”Cochrane Database Syst Rev.2006 Oct 18;2006(4):CD006162.doi: 10.1002/14651858.CD006162.pub2.PMID: 17054276
[4] Wierzbicki AS.”Rimonabant: endocannabinoid inhibition for the metabolic syndrome.”Int J Clin Pract.2006 Dec;60(12):1697-706.doi: 10.1111/j.1742-1241.2006.01210.x.PMID: 17109677
[5] Cox SL. "Rimonabant hydrochloride: he mea noiʻi no ka mālama ʻana i nā mea pilikia cardiovascular."Drugs Today (Barc).2005 Aug;41(8):499-508.doi: 10.1358/dot.2005.41.8.893709. PMID: 16234873
[6] Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A. "Rimonabant: he lāʻau antiobesity wale nō? ʻO nā hōʻike o kēia manawa ma kāna hopena pleiotropic.
